Caris Life Sciences, Inc.
CAI
$37.90
-$0.58-1.51%
NASDAQ
| 06/30/2025 | |||||
|---|---|---|---|---|---|
| Revenue | 50.02% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | 50.02% | ||||
| Cost of Revenue | 6.05% | ||||
| Gross Profit | 99.23% | ||||
| SG&A Expenses | 15.96% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 11.47% | ||||
| Operating Income | 68.96% | ||||
| Income Before Tax | 30.02% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | 30.02% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 30.02% | ||||
| EBIT | 68.96% | ||||
| EBITDA | 77.25% | ||||
| EPS Basic | -123.39% | ||||
| Normalized Basic EPS | 71.19% | ||||
| EPS Diluted | -123.39% | ||||
| Normalized Diluted EPS | 71.19% | ||||
| Average Basic Shares Outstanding | 82.24% | ||||
| Average Diluted Shares Outstanding | 82.24% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||